BNTX·Nasdaq·US
BioNTech
BioNTech is a biotechnology company focused on developing and commercializing immunotherapies, mRNA vaccines, and oncology treatments. Its revenue is driven by product sales and collaboration agreements, including its partnership with Pfizer on COVID-19 vaccines and its expanding oncology pipeline.
Recent Activity
Updated Oct 31, 2026
–BioNTech and DualityBio reported that their antibody-drug conjugate met its primary goal in a Phase 3 breast cancer study, but the companies said the benefit was modest and the impact may be limited in HER2-low breast cancer.
–BioNTech and Bristol Myers Squibb reported encouraging global Phase 2 data for pumitamig plus docetaxel in advanced non-small cell lung cancer after progression on immunotherapy plus chemotherapy, with responses in squamous and non-squamous disease across PD-L1 expression levels.
–BioNTech entered a clinical trial collaboration with Gilead Sciences to advance a Phase 3 trial of pumitamig combined with Gilead's TROP2-directed ADC sacituzumab govitecan in PD-L1 low or negative triple-negative breast cancer.
Past updates are part of the Pro plan.
Thematic Position
Relationship Groups
Relationship details are part of the Pro plan.